Loading...
Header Logo
Keywords
Last Name
Institution

Dr Anuradha Dube

Title[no position]
Institution[no institution name]
Address[no address]
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Jaiswal AK, Rao KB, Kushwaha P, Rawat K, Modukuri RK, Khare P, Joshi S, Mishra S, Rai A, Sashidhara KV, Dube A. Development of Leishmania donovani stably expressing DsRed for flow cytometry-based drug screening using chalcone thiazolyl-hydrazone as a new antileishmanial target. Int J Antimicrob Agents. 2016 Dec; 48(6):695-702. PMID: 27876275.
      View in: PubMed
    2. Tripathi P, Dwivedi P, Khatik R, Jaiswal AK, Dube A, Shukla P, Mishra PR. Development of 4-sulfated N-acetyl galactosamine anchored chitosan nanoparticles: A dual strategy for effective management of Leishmaniasis. Colloids Surf B Biointerfaces. 2015 Dec 01; 136:150-9. PMID: 26381698.
      View in: PubMed
    3. Das S, Shah P, Tandon R, Yadav NK, Sahasrabuddhe AA, Sundar S, Siddiqi MI, Dube A. Over-Expression of Cysteine Leucine Rich Protein Is Related to SAG Resistance in Clinical Isolates of Leishmania donovani. PLoS Negl Trop Dis. 2015 Aug; 9(8):e0003992. PMID: 26295340.
      View in: PubMed
    4. Gupta PK, Jaiswal AK, Asthana S, Teja B V, Shukla P, Shukla M, Sagar N, Dube A, Rath SK, Mishra PR. Synergistic enhancement of parasiticidal activity of amphotericin B using copaiba oil in nanoemulsified carrier for oral delivery: an approach for non-toxic chemotherapy. Br J Pharmacol. 2015 Jul; 172(14):3596-610. PMID: 25825339.
      View in: PubMed
    5. Chaurasia M, Pawar VK, Jaiswal AK, Dube A, Paliwal SK, Chourasia MK. Chondroitin nanocapsules enhanced doxorubicin induced apoptosis against leishmaniasis via Th1 immune response. Int J Biol Macromol. 2015 Aug; 79:27-36. PMID: 25931395.
      View in: PubMed
    6. Baharia RK, Tandon R, Sharma T, Suthar MK, Das S, Siddiqi MI, Saxena JK, Sundar S, Dube A. Correction: Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis. PLoS Negl Trop Dis. 2015 Apr; 9(4):e0003742. PMID: 25901962.
      View in: PubMed
    7. Baharia RK, Tandon R, Sharma T, Suthar MK, Das S, Siddiqi MI, Saxena JK, Sundar S, Sunder S, Dube A. Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis. PLoS Negl Trop Dis. 2015 Mar; 9(3):e0003557. PMID: 25745863.
      View in: PubMed
    8. Gupta PK, Jaiswal AK, Asthana S, Dube A, Mishra PR. Antigen presenting cells targeting and stimulation potential of lipoteichoic acid functionalized lipo-polymerosome: a chemo-immunotherapeutic approach against intracellular infectious disease. Biomacromolecules. 2015 Apr 13; 16(4):1073-87. PMID: 25671728.
      View in: PubMed
    9. Asthana S, Gupta PK, Jaiswal AK, Dube A, Chourasia MK. Overexpressed Macrophage Mannose Receptor Targeted Nanocapsules- Mediated Cargo Delivery Approach for Eradication of Resident Parasite: In Vitro and In Vivo Studies. Pharm Res. 2015 Aug; 32(8):2663-77. PMID: 25715698.
      View in: PubMed
    10. Kumar A, Misra P, Sisodia B, Shasany AK, Sundar S, Dube A. Proteomic analyses of membrane enriched proteins of Leishmania donovani Indian clinical isolate by mass spectrometry. Parasitol Int. 2015 Aug; 64(4):36-42. PMID: 25597695.
      View in: PubMed
    11. Jaiswal AK, Khare P, Joshi S, Rawat K, Yadav N, Sundar S, Dube A. Immunological consequences of stress-related proteins--cytosolic tryparedoxin peroxidase and chaperonin TCP20--identified in splenic amastigotes of Leishmania donovani as Th1 stimulatory, in experimental visceral leishmaniasis. Parasitology. 2015 Apr; 142(5):728-44. PMID: 25498563.
      View in: PubMed
    12. Asthana S, Jaiswal AK, Gupta PK, Dube A, Chourasia MK. Th-1 biased immunomodulation and synergistic antileishmanial activity of stable cationic lipid-polymer hybrid nanoparticle: biodistribution and toxicity assessment of encapsulated amphotericin B. Eur J Pharm Biopharm. 2015 Jan; 89:62-73. PMID: 25477079.
      View in: PubMed
    13. Gupta PK, Jaiswal AK, Asthana S, Verma A, Kumar V, Shukla P, Dwivedi P, Dube A, Mishra PR. Self assembled ionically sodium alginate cross-linked amphotericin B encapsulated glycol chitosan stearate nanoparticles: applicability in better chemotherapy and non-toxic delivery in visceral leishmaniasis. Pharm Res. 2015 May; 32(5):1727-40. PMID: 25425053.
      View in: PubMed
    14. Jaiswal AK, Khare P, Joshi S, Kushawaha PK, Sundar S, Dube A. Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis. PLoS One. 2014; 9(9):e108556. PMID: 25268700.
      View in: PubMed
    15. Joshi S, Rawat K, Yadav NK, Kumar V, Siddiqi MI, Dube A. Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches. Front Immunol. 2014; 5:380. PMID: 25202307.
      View in: PubMed
    16. Jain V, Gupta A, Pawar VK, Asthana S, Jaiswal AK, Dube A, Chourasia MK. Chitosan-assisted immunotherapy for intervention of experimental leishmaniasis via amphotericin B-loaded solid lipid nanoparticles. Appl Biochem Biotechnol. 2014 Oct; 174(4):1309-1330. PMID: 25106894.
      View in: PubMed
    17. Baharia RK, Tandon R, Sahasrabuddhe AA, Sundar S, Dube A. Nucleosomal histone proteins of L. donovani: a combination of recombinant H2A, H2B, H3 and H4 proteins were highly immunogenic and offered optimum prophylactic efficacy against Leishmania challenge in hamsters. PLoS One. 2014; 9(6):e97911. PMID: 24926878.
      View in: PubMed
    18. Gupta PK, Asthana S, Jaiswal AK, Kumar V, Verma AK, Shukla P, Dwivedi P, Dube A, Mishra PR. Exploitation of lectinized lipo-polymerosome encapsulated Amphotericin B to target macrophages for effective chemotherapy of visceral leishmaniasis. Bioconjug Chem. 2014 Jun 18; 25(6):1091-102. PMID: 24842628.
      View in: PubMed
    19. Tandon R, Chandra S, Baharia RK, Das S, Misra P, Kumar A, Siddiqi MI, Sundar S, Dube A. Characterization of the proliferating cell nuclear antigen of Leishmania donovani clinical isolates and its association with antimony resistance. Antimicrob Agents Chemother. 2014 Jun; 58(6):2997-3007. PMID: 24614385.
      View in: PubMed
    20. Khatik R, Dwivedi P, Khare P, Kansal S, Dube A, Mishra PR, Dwivedi AK. Development of targeted 1,2-diacyl-sn-glycero-3-phospho-l-serine-coated gelatin nanoparticles loaded with amphotericin B for improved in vitro and in vivo effect in leishmaniasis. Expert Opin Drug Deliv. 2014 May; 11(5):633-46. PMID: 24606222.
      View in: PubMed
    21. Gupta PK, Jaiswal AK, Kumar V, Verma A, Dwivedi P, Dube A, Mishra PR. Covalent functionalized self-assembled lipo-polymerosome bearing amphotericin B for better management of leishmaniasis and its toxicity evaluation. Mol Pharm. 2014 Mar 03; 11(3):951-63. PMID: 24495144.
      View in: PubMed
    22. Kumar A, Misra P, Sisodia B, Shasany AK, Sundar S, Dube A. Mass spectrometry-based proteomic analysis of Leishmania donovani soluble proteins in Indian clinical isolate. Pathog Dis. 2014 Feb; 70(1):84-7. PMID: 24115687.
      View in: PubMed
    23. Gupta R, Kumar V, Kushawaha PK, Tripathi CP, Joshi S, Sahasrabuddhe AA, Mitra K, Sundar S, Siddiqi MI, Dube A. Characterization of glycolytic enzymes--rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis. PLoS One. 2014; 9(1):e86073. PMID: 24475071.
      View in: PubMed
    24. Khare P, Jaiswal AK, Tripathi CD, Joshi S, Sundar S, Dube A. Efficacy of Leishmania donovani trypanothione reductase, identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis. Parasitol Res. 2014 Mar; 113(3):851-62. PMID: 24370734.
      View in: PubMed
    25. Das S, Shah P, Baharia RK, Tandon R, Khare P, Sundar S, Sahasrabuddhe AA, Siddiqi MI, Dube A. Over-expression of 60s ribosomal L23a is associated with cellular proliferation in SAG resistant clinical isolates of Leishmania donovani. PLoS Negl Trop Dis. 2013; 7(12):e2527. PMID: 24340105.
      View in: PubMed
    26. Asthana S, Gupta PK, Chaurasia M, Dube A, Chourasia MK. Polymeric colloidal particulate systems: intelligent tools for intracellular targeting of antileishmanial cargos. Expert Opin Drug Deliv. 2013 Dec; 10(12):1633-51. PMID: 24147603.
      View in: PubMed
    27. Kansal S, Tandon R, Verma PR, Dube A, Mishra PR. Development of doxorubicin loaded novel core shell structured nanocapsules for the intervention of visceral leishmaniasis. J Microencapsul. 2013; 30(5):441-50. PMID: 23534494.
      View in: PubMed
    28. Asthana S, Jaiswal AK, Gupta PK, Pawar VK, Dube A, Chourasia MK. Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules. Antimicrob Agents Chemother. 2013 Apr; 57(4):1714-22. PMID: 23357762.
      View in: PubMed
    29. Kumar A, Misra P, Dube A. Amplified fragment length polymorphism: an adept technique for genome mapping, genetic differentiation, and intraspecific variation in protozoan parasites. Parasitol Res. 2013 Feb; 112(2):457-66. PMID: 23254590.
      View in: PubMed
    30. Tandon R, Misra P, Soni VK, Bano N, Misra-Bhattacharya S, Dube A. Unresponsiveness of Mycobacterium w vaccine in managing acute and chronic Leishmania donovani infections in mouse and hamster. Parasitology. 2013 Apr; 140(4):435-44. PMID: 23253783.
      View in: PubMed
    31. Kushawaha PK, Gupta R, Tripathi CD, Khare P, Jaiswal AK, Sundar S, Dube A. Leishmania donovani triose phosphate isomerase: a potential vaccine target against visceral leishmaniasis. PLoS One. 2012; 7(9):e45766. PMID: 23049855.
      View in: PubMed
    32. Kansal S, Tandon R, Dwivedi P, Misra P, Verma PR, Dube A, Mishra PR. Development of nanocapsules bearing doxorubicin for macrophage targeting through the phosphatidylserine ligand: a system for intervention in visceral leishmaniasis. J Antimicrob Chemother. 2012 Nov; 67(11):2650-60. PMID: 22872448.
      View in: PubMed
    33. Kushawaha PK, Gupta R, Tripathi CD, Sundar S, Dube A. Evaluation of Leishmania donovani protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral Leishmaniasis. PLoS One. 2012; 7(4):e35670. PMID: 22539989.
      View in: PubMed
    34. Gupta R, Kushawaha PK, Tripathi CD, Sundar S, Dube A. A novel recombinant Leishmania donovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis. Int J Parasitol. 2012 May 01; 42(5):429-35. PMID: 22502587.
      View in: PubMed
    35. Khare P, Gupta AK, Gajula PK, Sunkari KY, Jaiswal AK, Das S, Bajpai P, Chakraborty TK, Dube A, Saxena AK. Identification of novel S-adenosyl-L-homocysteine hydrolase inhibitors through homology-model-based virtual screening, synthesis, and biological evaluation. J Chem Inf Model. 2012 Mar 26; 52(3):777-91. PMID: 22324915.
      View in: PubMed
    36. Kumari S, Misra P, Tandon R, Samant M, Sundar S, Dube A. Leishmania donovani: immunostimulatory cellular responses of membrane and soluble protein fractions of splenic amastigotes in cured patient and hamsters. PLoS One. 2012; 7(1):e30746. PMID: 22292030.
      View in: PubMed
    37. Gupta R, Kushawaha PK, Samant M, Jaiswal AK, Baharia RK, Dube A. Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses. J Antimicrob Chemother. 2012 Feb; 67(2):440-3. PMID: 22121191.
      View in: PubMed
    38. Kushawaha PK, Gupta R, Sundar S, Sahasrabuddhe AA, Dube A. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-? and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge. J Immunol. 2011 Dec 15; 187(12):6417-27. PMID: 22079980.
      View in: PubMed
    39. Pal A, Gupta S, Jaiswal A, Dube A, Vyas SP. Development and evaluation of tripalmitin emulsomes for the treatment of experimental visceral leishmaniasis. J Liposome Res. 2012 Mar; 22(1):62-71. PMID: 21740098.
      View in: PubMed
    40. Singodia D, Verma A, Khare P, Dube A, Mitra K, Mishra PR. Investigations on feasibility of in situ development of amphotericin B liposomes for industrial applications. J Liposome Res. 2012 Mar; 22(1):8-17. PMID: 21682670.
      View in: PubMed
    41. Singh P, Gupta A, Jaiswal A, Dube A, Mishra S, Chaurasia MK. Design and development of Amphotericin B bearing polycaprolactone microparticles for macrophage targeting. J Biomed Nanotechnol. 2011 Feb; 7(1):50-1. PMID: 21485798.
      View in: PubMed
    42. Sharma S, Kumar P, Jaiswal A, Dube A, Gupta S. Development and characterization of doxorubicin loaded microparticles against experimental visceral leishmaniasis. J Biomed Nanotechnol. 2011 Feb; 7(1):135-6. PMID: 21485839.
      View in: PubMed
    43. Kunjachan S, Gupta S, Dwivedi AK, Dube A, Chourasia MK. Chitosan-based macrophage-mediated drug targeting for the treatment of experimental visceral leishmaniasis. J Microencapsul. 2011; 28(4):301-10. PMID: 21545321.
      View in: PubMed
    44. Kumar A, Sisodia B, Misra P, Sundar S, Shasany AK, Dube A. Proteome mapping of overexpressed membrane-enriched and cytosolic proteins in sodium antimony gluconate (SAG) resistant clinical isolate of Leishmania donovani. Br J Clin Pharmacol. 2010 Oct; 70(4):609-17. PMID: 20840452.
      View in: PubMed
    45. Kaur J, Singh N, Singh BK, Dube A, Tripathi RP, Singh P, Singh N. Leishmania donovani: oral therapy with glycosyl 1,4-dihydropyridine analogue showing apoptosis like phenotypes targeting pteridine reductase 1 in intracellular amastigotes. Exp Parasitol. 2010 Jul; 125(3):310-4. PMID: 20219462.
      View in: PubMed
    46. Misra P, Sashidhara KV, Singh SP, Kumar A, Gupta R, Chaudhaery SS, Gupta SS, Majumder HK, Saxena AK, Dube A. 16alpha-Hydroxycleroda-3,13 (14)Z-dien-15,16-olide from Polyalthia longifolia: a safe and orally active antileishmanial agent. Br J Pharmacol. 2010 Mar; 159(5):1143-50. PMID: 20136832.
      View in: PubMed
    47. Nahar M, Dubey V, Mishra D, Mishra PK, Dube A, Jain NK. In vitro evaluation of surface functionalized gelatin nanoparticles for macrophage targeting in the therapy of visceral leishmaniasis. J Drug Target. 2010 Feb; 18(2):93-105. PMID: 19640212.
      View in: PubMed
    48. Kumar N, Gupta S, Dube A, Vyas SP. Emerging role of vesicular carriers for therapy of visceral leishmaniasis: conventional versus novel. Crit Rev Ther Drug Carrier Syst. 2010; 27(6):461-507. PMID: 21175419.
      View in: PubMed
    49. Gupta GK, Kansal S, Misra P, Dube A, Mishra PR. Uptake of biodegradable gel-assisted LBL nanomatrix by Leishmania donovani-infected macrophages. AAPS PharmSciTech. 2009; 10(4):1343-7. PMID: 19904614.
      View in: PubMed
    50. Kumar A, Boggula VR, Misra P, Sundar S, Shasany AK, Dube A. Amplified fragment length polymorphism (AFLP) analysis is useful for distinguishing Leishmania species of visceral and cutaneous forms. Acta Trop. 2010 Feb; 113(2):202-6. PMID: 19854144.
      View in: PubMed
    51. Dangi A, Vedi S, Nag JK, Paithankar S, Singh MP, Kar SK, Dube A, Misra-Bhattacharya S. Tetracycline treatment targeting Wolbachia affects expression of an array of proteins in Brugia malayi parasite. Proteomics. 2009 Sep; 9(17):4192-208. PMID: 19722191.
      View in: PubMed
    52. Dube A, Gupta R, Singh N. Reporter genes facilitating discovery of drugs targeting protozoan parasites. Trends Parasitol. 2009 Sep; 25(9):432-9. PMID: 19720564.
      View in: PubMed
    53. Singh N, Kaur J, Kumar P, Gupta S, Singh N, Ghosal A, Dutta A, Kumar A, Tripathi R, Siddiqi MI, Mandal C, Dube A. An orally effective dihydropyrimidone (DHPM) analogue induces apoptosis-like cell death in clinical isolates of Leishmania donovani overexpressing pteridine reductase 1. Parasitol Res. 2009 Oct; 105(5):1317-25. PMID: 19621245.
      View in: PubMed
    54. Samant M, Gupta R, Kumari S, Misra P, Khare P, Kushawaha PK, Sahasrabuddhe AA, Dube A. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis. J Immunol. 2009 Jul 01; 183(1):470-9. PMID: 19542458.
      View in: PubMed
    55. Misra P, Kumar A, Khare P, Gupta S, Kumar N, Dube A. Pro-apoptotic effect of the landrace Bangla Mahoba of Piper betle on Leishmania donovani may be due to the high content of eugenol. J Med Microbiol. 2009 Aug; 58(Pt 8):1058-66. PMID: 19528177.
      View in: PubMed
    56. Singh N, Gupta R, Jaiswal AK, Sundar S, Dube A. Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening. J Antimicrob Chemother. 2009 Aug; 64(2):370-4. PMID: 19525291.
      View in: PubMed
    57. Kumar A, Boggula VR, Sundar S, Shasany AK, Dube A. Identification of genetic markers in sodium antimony gluconate (SAG) sensitive and resistant Indian clinical isolates of Leishmania donovani through amplified fragment length polymorphism (AFLP). Acta Trop. 2009 Apr; 110(1):80-5. PMID: 19283900.
      View in: PubMed
    58. Khaliq T, Misra P, Gupta S, Reddy KP, Kant R, Maulik PR, Dube A, Narender T. Peganine hydrochloride dihydrate an orally active antileishmanial agent. Bioorg Med Chem Lett. 2009 May 01; 19(9):2585-6. PMID: 19339182.
      View in: PubMed
    59. Maurya R, Gupta P, Chand K, Kumar M, Dixit P, Singh N, Dube A. Constituents of Tinospora sinensis and their antileishmanial activity against Leishmania donovani. Nat Prod Res. 2009; 23(12):1134-43. PMID: 19662579.
      View in: PubMed
    60. Kumari S, Samant M, Khare P, Misra P, Dutta S, Kolli BK, Sharma S, Chang KP, Dube A. Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis. Eur J Immunol. 2009 Jan; 39(1):178-91. PMID: 19053149.
      View in: PubMed
    61. Kumari S, Kumar A, Samant M, Singh N, Dube A. Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics. Curr Drug Targets. 2008 Nov; 9(11):938-47. PMID: 18991606.
      View in: PubMed
    62. Kumari S, Samant M, Misra P, Khare P, Sisodia B, Shasany AK, Dube A. Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis. Vaccine. 2008 Oct 23; 26(45):5700-11. PMID: 18762224.
      View in: PubMed
    63. Misra P, Khaliq T, Dixit A, SenGupta S, Samant M, Kumari S, Kumar A, Kushawaha PK, Majumder HK, Saxena AK, Narender T, Dube A. Antileishmanial activity mediated by apoptosis and structure-based target study of peganine hydrochloride dihydrate: an approach for rational drug design. J Antimicrob Chemother. 2008 Nov; 62(5):998-1002. PMID: 18694906.
      View in: PubMed
    64. Kumari S, Samant M, Khare P, Sundar S, Sinha S, Dube A. Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa. Vaccine. 2008 Sep 02; 26(37):4813-8. PMID: 18656517.
      View in: PubMed
    65. Kumar P, Kumar A, Verma SS, Dwivedi N, Singh N, Siddiqi MI, Tripathi RP, Dube A, Singh N. Leishmania donovani pteridine reductase 1: biochemical properties and structure-modeling studies. Exp Parasitol. 2008 Sep; 120(1):73-9. PMID: 18617167.
      View in: PubMed
    66. Singh N, Kumar R, Gupta S, Dube A, Lakshmi V. Antileishmanial activity in vitro and in vivo of constituents of sea cucumber Actinopyga lecanora. Parasitol Res. 2008 Jul; 103(2):351-4. PMID: 18452039.
      View in: PubMed
    67. Manandhar KD, Yadav TP, Prajapati VK, Kumar S, Rai M, Dube A, Srivastava ON, Sundar S. Antileishmanial activity of nano-amphotericin B deoxycholate. J Antimicrob Chemother. 2008 Aug; 62(2):376-80. PMID: 18453526.
      View in: PubMed
    68. Kumari S, Kumar A, Samant M, Sundar S, Singh N, Dube A. Proteomic approaches for discovery of new targets for vaccine and therapeutics against visceral leishmaniasis. Proteomics Clin Appl. 2008 Mar; 2(3):372-86. PMID: 21136840.
      View in: PubMed
    69. Singh N, Kumar A, Gupta P, Chand K, Samant M, Maurya R, Dube A. Evaluation of antileishmanial potential of Tinospora sinensis against experimental visceral leishmaniasis. Parasitol Res. 2008 Feb; 102(3):561-5. PMID: 18080140.
      View in: PubMed
    70. Gupta S, Dube A, Vyas SP. Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis. J Drug Target. 2007 Jul; 15(6):437-44. PMID: 17613662.
      View in: PubMed
    71. Singh N, Samant M, Gupta SK, Kumar A, Dube A. Age-influenced population kinetics and immunological responses of Leishmania donovani in hamsters. Parasitol Res. 2007 Sep; 101(4):919-24. PMID: 17484071.
      View in: PubMed
    72. Gupta SK, Sisodia BS, Sinha S, Hajela K, Naik S, Shasany AK, Dube A. Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes. Proteomics. 2007 Mar; 7(5):816-23. PMID: 17295358.
      View in: PubMed
    73. Dube A, Singh N, Saxena A, Lakshmi V. Antileishmanial potential of a marine sponge, Haliclona exigua (Kirkpatrick) against experimental visceral leishmaniasis. Parasitol Res. 2007 Jul; 101(2):317-24. PMID: 17294216.
      View in: PubMed
    74. Garg R, Dube A. Animal models for vaccine studies for visceral leishmaniasis. Indian J Med Res. 2006 Mar; 123(3):439-54. PMID: 16778322.
      View in: PubMed
    75. Garg R, Gupta SK, Tripathi P, Hajela K, Sundar S, Naik S, Dube A. Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis. Vaccine. 2006 Apr 05; 24(15):2900-9. PMID: 16448729.
      View in: PubMed
    76. Sharma SK, Dube A, Nadeem A, Khan S, Saleem I, Garg R, Mohammad O. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis. Vaccine. 2006 Mar 10; 24(11):1800-10. PMID: 16310900.
      View in: PubMed
    77. Mishra PK, Singh N, Ahmad G, Dube A, Maurya R. Glycolipids and other constituents from Desmodium gangeticum with antileishmanial and immunomodulatory activities. Bioorg Med Chem Lett. 2005 Oct 15; 15(20):4543-6. PMID: 16099649.
      View in: PubMed
    78. Dube A, Singh N, Sundar S, Singh N. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res. 2005 Jun; 96(4):216-23. PMID: 15868188.
      View in: PubMed
    79. Singh N, Mishra PK, Kapil A, Arya KR, Maurya R, Dube A. Efficacy of Desmodium gangeticum extract and its fractions against experimental visceral leishmaniasis. J Ethnopharmacol. 2005 Apr 08; 98(1-2):83-8. PMID: 15763367.
      View in: PubMed
    80. Garg R, Srivastava JK, Pal A, Naik S, Dube A. Isolation of integral membrane proteins of Leishmania promastigotes and evaluation of their prophylactic potential in hamsters against experimental visceral leishmaniasis. Vaccine. 2005 Jan 19; 23(9):1189-96. PMID: 15629362.
      View in: PubMed
    81. Garg R, Singh N, Dube A. Intake of nutrient supplements affects multiplication of Leishmania donovani in hamsters. Parasitology. 2004 Dec; 129(Pt 6):685-91. PMID: 15648691.
      View in: PubMed
    82. Sharma P, Singh N, Garg R, Haq W, Dube A. Efficacy of human beta-casein fragment (54-59) and its synthetic analogue compound 89/215 against Leishmania donovani in hamsters. Peptides. 2004 Nov; 25(11):1873-81. PMID: 15501518.
      View in: PubMed
    83. Singh N, Dube A. Short report: fluorescent Leishmania: application to anti-leishmanial drug testing. Am J Trop Med Hyg. 2004 Oct; 71(4):400-2. PMID: 15516633.
      View in: PubMed
    84. Dube A, Murthy PK, Puri SK, Misra-Bhattacharya S. Presbytis entellus: a primate model for parasitic disease research. Trends Parasitol. 2004 Aug; 20(8):358-60. PMID: 15246317.
      View in: PubMed
    85. Misra A, Dube A, Naik S. Immune responses in normal Indian langur monkeys (Presbytis entellus)--a primate model for visceral leishmaniasis. J Med Primatol. 2004 Apr; 33(2):65-9. PMID: 15061718.
      View in: PubMed
    86. Srivastava JK, Misra A, Sharma P, Srivastava B, Naik S, Dube A. Prophylactic potential of autoclaved Leishmania donovani with BCG against experimental visceral leishmaniasis. Parasitology. 2003 Aug; 127(Pt 2):107-14. PMID: 12954011.
      View in: PubMed
    87. Dube A, Srivastava JK, Sharma P, Chaturvedi A, Katiyar JC, Naik S. Leishmania donovani: cellular and humoral immune responses in Indian langur monkeys, Presbytis entellus. Acta Trop. 1999 May 25; 73(1):37-48. PMID: 10379815.
      View in: PubMed
    88. Dube A, Sharma P, Srivastava JK, Misra A, Naik S, Katiyar JC. Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG. Parasitology. 1998 Mar; 116 ( Pt 3):219-21. PMID: 9550214.
      View in: PubMed
    Dube's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description